Regulacje i polityka gospodarcza · 26/12/2000

NIH Grants Exclusive License for Cataract Prevention Treatment

The National Institutes of Health (NIH) is considering granting an exclusive license to SL Pharmaceuticals for the use of a patent for hydroxylamine compositions to prevent or delay cataract formation, with the potential for human therapeutics and diagnostics.